LOW-VOLUME · SEX-BALANCED

eravacycline Side Effects

eravacycline (also sold as Xerava) is a LOW-VOLUME FAERS extract #516 of 524 by FAERS report count. Still opens on SEX-BALANCED: 35% of sex-coded reports are female (51 F / 95 M).

Data updated 2026-05-15

205
FAERS reports

Thinner FAERS book - still a temporal association ledger, not proof of cause. Methodology.

eravacycline reporting skew - 35% of sex-coded reports are female (51 F / 95 M). Volume band LOW-VOLUME #516 of 524 by FAERS report count; caseload TRACE-CASE.

Thinner FAERS extract for eravacycline (Xerava) (205 reports #516 of 524 by FAERS report count). 35% of sex-coded reports are female (51 F / 95 M). Sparse books still carry named reaction rows when present; not medical advice.

Counts from the openFDA FAERS extract (2019–2025). Stamps TRACE-CASE · DEATH-HEAVY · HOSP-MID · SEX-BALANCED.

BLOOD FIBRINOGEN DECREASED leads 16 of 205 reports

BLOOD FIBRINOGEN DECREASED
16
NAUSEA
15
THROMBOCYTOPENIA
14
MULTIPLE ORGAN DYSFUNCTION SYNDROME
13
LACTIC ACIDOSIS
11
HYPERTRANSAMINASAEMIA
10
DIARRHOEA
9
PANCREATITIS
8
ACUTE RESPIRATORY DISTRESS SYNDROME
6
CONDITION AGGRAVATED
6
ENTEROCOCCAL INFECTION
6
PROTHROMBIN TIME PROLONGED
6
SEPSIS
6
BLOOD BILIRUBIN INCREASED
5
DRUG INEFFECTIVE FOR UNAPPROVED INDICATION
5
GASTROINTESTINAL HAEMORRHAGE
5

Who reports · age peak 45-64 (SEX-BALANCED)

Sex coding · SEX-BALANCED

Female 51 (35%)
Male 95 (65%)

Age peak 45-64 (45 reports)

0-17 6 (5%)
18-44 36 (29%)
45-64 45 (36%)
65-74 26 (21%)
75+ 11 (9%)

FAERS filings rising toward 2025

19
20
21
22
23
24
25

Reactions in Death Reports

Death-mentioned subset is HEAVY here (33 reports, 16.1%). Top co-reported reactions in that subset - voluntary, not causal.

Reaction Reports
MULTIPLE ORGAN DYSFUNCTION SYNDROME 13
ACUTE RESPIRATORY DISTRESS SYNDROME 6
THROMBOCYTOPENIA 5
BLOOD FIBRINOGEN DECREASED 4
HYPERTRANSAMINASAEMIA 4
LACTIC ACIDOSIS 4
SHOCK 4
BLASTOMYCOSIS 3
CONDITION AGGRAVATED 3
ENTEROCOCCAL INFECTION 3
MYCOBACTERIUM ABSCESSUS INFECTION 3
PNEUMONITIS 3
SEPSIS 3
SEPTIC SHOCK 3
DISSEMINATED BLASTOMYCOSIS 2
PULMONARY BLASTOMYCOSIS 2
ACTIVATED PARTIAL THROMBOPLASTIN TIME PROLONGED 1

Reactions in Hospitalization Reports

Hospitalization mid-share (57, 27.8%). Co-reported reactions:

Reaction Reports
BLOOD FIBRINOGEN DECREASED 9
HYPERTRANSAMINASAEMIA 8
LACTIC ACIDOSIS 8
THROMBOCYTOPENIA 8
ACUTE RESPIRATORY DISTRESS SYNDROME 6
MULTIPLE ORGAN DYSFUNCTION SYNDROME 6
BLASTOMYCOSIS 3
BLOOD BILIRUBIN INCREASED 3
ENTEROCOCCAL INFECTION 3
NAUSEA 3
PNEUMONITIS 3
PROTHROMBIN TIME PROLONGED 3
SEPSIS 3
BILIRUBIN CONJUGATED INCREASED 2
COAGULOPATHY 2
CONDITION AGGRAVATED 2
DIARRHOEA 2
How to read eravacycline FAERS figures (TRACE-CASE · DEATH-HEAVY · HOSP-MID)

FAERS holds 205 voluntary reports linked to eravacycline (Xerava), 2019-2025. Death is listed on 33 (16.1%). Hospitalization appears on 57 (27.8%). Top co-reported indication: Product Used For Unknown Indication.

Sparse extract - named reactions and SEX-BALANCED skew still differ by drug; not a complete safety profile.

Read with eravacycline

Peers ranked by ABS(total_reports), then an ABS(death_share) pole; guide hop follows DEATH-HEAVY · HOSP-MID stamps.